5360-04-3

Usage

InChI:InChI=1/C10H22O5Si2/c1-9(11)13-7-16(3,4)15-17(5,6)8-14-10(2)12/h7-8H2,1-6H3

Upstream product

• 17201-83-1 1-chloromethylpentamethyldisiloxane 
• 127-08-2 potassium acetate 
• 64-19-7 acetic acid 
• 2362-10-9 1,3-Bis(chloromethyl)-1,1,3,3-tetramethyldisiloxane 
• 107-46-0 Hexamethyldisiloxane 
• 2351-13-5 1,3-bis(bromomethyl)-1,1,3,3-tetramethyldisiloxane 

Downstream Products

• 79-20-9 acetic acid methyl ester 
• 541-05-9 Hexamethylcyclotrisiloxane 
• 18641-25-3 1,3-bis-(3,5-dinitro-benzoyloxymethyl)-1,1,3,3-tetramethyl-disiloxane 
• 5833-59-0 (1,1,3,3-tetramethyldisiloxane-1,3-diyl)dimethanol 

Relevant academic research and scientific papers

SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME

Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

Synthesis and characterization of some bis(hydroxyalkyl)- and bis(hydroxyester)-functionalized disiloxanes

Novel hydroxyester disiloxanes (1,3-bis(6-hydroxyhexa noylmethyl)-1,1,3,3- tetramethyl disiloxane and 3-bis(2-hydroxypropanoylmethyl)tetramethyl disiloxane) were synthesized, and preparation of other known monomers, namely 1,3-bis(hydroxypropyl)-1,1,3,3-tetramethyl disiloxane, 1,3- bis(hydroxyethoxypropyl)-1,1,3,3-tetramethyl disiloxane and 1,3- bis(hydroxymethyl)-1,1,3,3-tetramethyl disiloxane was developed to obtain better yields and reduce production time and expense. All compounds were characterized by infrared spectroscopy, using 1H NMR, 13C NMR, and 29Si NMR and were reacted with diisocyanates, resulting in poly(siloxane-urethane) copolymers with unique properties.